Home / 2025 (Page 140)

Cricket legend M.S. Dhoni and Emcure Pharma’s Whole-Time Director Namita Thapar have come together in a powerful conversation to highlight the urgent need to prioritize women’s health. A video shared by Namita on her podcast on women’s health, Uncondition Yourself with Namita, highlights how women, despite

READ MORE

Dr. Azad Moopen, Founder & Chairman, Aster DM Healthcare       “The Union Budget 2025 strengthens India’s commitment to a more resilient and inclusive healthcare system, ensuring accessibility, affordability, and quality care for all. The addition of 75,000 new medical seats over will address the long-standing healthcare workforce shortage.

READ MORE

Cotecna Life Sciences India Private Limited, formerly Geo-Chem Pharma, is proud to announce the inauguration of its new, state-of-the-art laboratory in Mumbai. This development represents a significant step in supporting the rapid growth of India’s pharmaceutical industry and demonstrates Cotecna’s dedication to fostering innovation, quality,

READ MORE

India’s Largest Integrated Healthcare Provider and New Jersey’s Largest Healthcare Network Join Forces to Solve Healthcare’s Most Pressing Challenges The affiliation with Apollo Hospitals Group supports Hackensack Meridian Health’s commitment to the Indian community, with New Jersey having the second-largest Indian population in the United States Apollo

READ MORE

Supporting Caregivers with Nutritious Meals & Financial Relief for Better Health and Well-being In a bustling city where hospitals brim with patients and their caregivers, the challenge of accessing healthy, affordable meals often compounds the emotional and logistical strain of caregiving. Recognizing this critical gap, Akshaya

READ MORE

The 2 new mobile Medical units will provide free medical care to underserved populations in Sankari, Surat and Khedbrahma in Sabarkantha Districts of Gujarat. Aster Volunteers Mobile Medical Units through its global network of 50 units have treated over 1.4 million individuals across India,

READ MORE

Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine Dimesylate Capsules in strengths

READ MORE

Q3FY2025 Performance Highlights Revenue at ₹11,537m, grew 14.6% YoY Gross margin at ₹6,735m, grew 25.1% YoY EBITDA grew 46.9% YoY to ₹2,103m with EBITDA margin at 18.2%, grew 401bps YoY US revenue at $73m, grew 13.7% YoY Q3FY25 Reported PAT at ₹900m Reported

READ MORE